Analyst consensus rating
Recursion Pharmaceuticals Analyst Rating: Buy
RXRX is rated Buy by 6 analysts with a $7.22 target. As of 2026-08-23.
Direct answer
Recursion Pharmaceuticals's consensus rating is Buy.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $7.22.
Forecast evidence checked August 23, 2026.
Get free Recursion Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $3.50
- Average price target
- $7.22
- High price target
- $10.00
- Low price target
- $4.00
- Low target gap
- +14.3%
- Target upside
- +106.2%
- High target gap
- +185.7%
- Target range width
- 171.4%
- Consensus rating
- Buy
- Analysts
- 6
- Evidence date
- August 23, 2026
- Valid through
- August 30, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Recursion Pharmaceuticals?
Recursion Pharmaceuticals has a verified Buy consensus. The same dataset has an average price target of $7.22.
How far are Recursion Pharmaceuticals's low and high targets from the recorded price?
The low target implies +14.3%, while the high target implies +185.7%.
How many analysts are included in Recursion Pharmaceuticals's consensus?
The verified consensus includes 6 analysts.
How is Recursion Pharmaceuticals's target upside or downside calculated?
The average target of $7.22 is divided by the recorded price of $3.50, then one is subtracted to produce +106.2%. This does not guarantee a future return.
When was Recursion Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-08-23. The dataset is valid through 2026-08-30.